allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le
Company profile
Ticker
ALLO
Exchange
Website
CEO
David D. Chang
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
ALLO stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
26 Apr 24
ARS
2023 FY
Annual report to shareholders
23 Apr 24
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
S-8
Registration of securities for employees
14 Mar 24
S-3
Shelf registration
14 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
POSASR
Automatic shelf registration (post-effective amendment)
14 Mar 24
8-K
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023
14 Mar 24
10-K/A
2022 FY
Annual report (amended)
14 Mar 24
Transcripts
ALLO
Earnings call transcript
2023 Q4
14 Mar 24
ALLO
Earnings call transcript
2023 Q3
2 Nov 23
ALLO
Earnings call transcript
2023 Q2
2 Aug 23
ALLO
Earnings call transcript
2023 Q1
3 May 23
ALLO
Earnings call transcript
2022 Q4
28 Feb 23
ALLO
Earnings call transcript
2022 Q3
3 Nov 22
ALLO
Earnings call transcript
2022 Q2
10 Aug 22
ALLO
Earnings call transcript
2022 Q1
5 May 22
ALLO
Earnings call transcript
2021 Q4
24 Feb 22
ALLO
Earnings call transcript
2021 Q3
5 Nov 21
Latest ownership filings
4
TIMOTHY L. MOORE
24 Apr 24
144
Notice of proposed sale of securities
22 Apr 24
4
David D Chang
18 Mar 24
144
Notice of proposed sale of securities
14 Mar 24
4
Geoffrey M. Parker
6 Mar 24
SC 13G/A
Belldegrun Arie
14 Feb 24
SC 13G/A
Chang David D
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
TIMOTHY L. MOORE
31 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 79.54 mm | 79.54 mm | 79.54 mm | 79.54 mm | 79.54 mm | 79.54 mm |
Cash burn (monthly) | 28.50 mm | 425.92 k | 20.99 mm | 28.24 mm | 18.51 mm | 20.51 mm |
Cash used (since last report) | 196.97 mm | 2.94 mm | 145.05 mm | 195.17 mm | 127.91 mm | 141.73 mm |
Cash remaining | -117.43 mm | 76.59 mm | -65.52 mm | -115.64 mm | -48.37 mm | -62.19 mm |
Runway (months of cash) | -4.1 | 179.8 | -3.1 | -4.1 | -2.6 | -3.0 |
Institutional ownership, Q3 2023
96.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 157 |
Opened positions | 14 |
Closed positions | 30 |
Increased positions | 67 |
Reduced positions | 35 |
13F shares | Current |
---|---|
Total value | 405.34 bn |
Total shares | 164.86 mm |
Total puts | 41.70 k |
Total calls | 5.90 k |
Total put/call ratio | 7.1 |
Largest owners | Shares | Value |
---|---|---|
FMR | 25.14 mm | $79.71 bn |
PFE Pfizer | 22.03 mm | $103.33 mm |
TPG GP A | 18.72 mm | $59.33 bn |
Vanguard | 10.59 mm | $33.56 bn |
BLK Blackrock | 8.89 mm | $28.19 bn |
STT State Street | 8.20 mm | $26.00 bn |
Seaview Trust | 7.04 mm | $105.05 mm |
JPM JPMorgan Chase & Co. | 6.91 mm | $21.91 bn |
Woodline Partners | 5.31 mm | $16.85 bn |
Primecap Management | 5.28 mm | $16.75 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Apr 24 | Moore Timothy L. | Common Stock | Payment of exercise | Dispose F | No | No | 3.4671 | 17,360 | 60.19 k | 265,459 |
14 Mar 24 | Chang David D | Common Stock | Payment of exercise | Dispose F | No | No | 4.33 | 53,393 | 231.19 k | 4,465,278 |
30 Jan 24 | Parker Geoffrey M. | Common Stock | Buy | Acquire P | No | No | 3.595 | 190 | 683.05 | 819,590 |
25 Jan 24 | Chang David D | Common Stock | Grant | Acquire A | No | No | 0 | 317,800 | 0.00 | 4,513,203 |
25 Jan 24 | Chang David D | Stock Option Common Stock | Grant | Acquire A | No | No | 3.2 | 1,123,535 | 3.60 mm | 1,123,535 |
25 Jan 24 | Zachary Roberts | Common Stock | Grant | Acquire A | No | No | 0 | 140,000 | 0.00 | 515,253 |
25 Jan 24 | Zachary Roberts | Stock Option Common Stock | Grant | Acquire A | No | No | 3.2 | 494,949 | 1.58 mm | 494,949 |
News
Allogene Therapeutics Awarded $15M Grant From California Institute For Regenerative Medicine To Advance Development Of Allogeneic CAR T In Renal Cell Carcinoma
26 Apr 24
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
18 Apr 24
HC Wainwright & Co. Reiterates Buy on Allogene Therapeutics, Maintains $10 Price Target
19 Mar 24
RBC Capital Reiterates Outperform on Allogene Therapeutics, Maintains $10 Price Target
15 Mar 24
Recap: Allogene Therapeutics Q4 Earnings
14 Mar 24
Press releases
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
26 Apr 24
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
12 Mar 24
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
5 Mar 24
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
28 Feb 24
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
16 Feb 24